| ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis X Montalban, R Gold, AJ Thompson, S Otero-Romero, MP Amato, ... Multiple Sclerosis Journal 24 (2), 96-120, 2018 | 904 | 2018 |
| Defining high, medium and low impact prognostic factors for developing multiple sclerosis M Tintore, À Rovira, J Río, S Otero-Romero, G Arrambide, C Tur, ... Brain 138 (7), 1863-1874, 2015 | 569 | 2015 |
| Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial AM Borobia, AJ Carcas, M Pérez-Olmeda, L Castaño, MJ Bertran, ... The Lancet 398 (10295), 121-130, 2021 | 416 | 2021 |
| Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper S Otero-Romero, J Sastre-Garriga, G Comi, HP Hartung, ... Multiple Sclerosis Journal 22 (11), 1386-1396, 2016 | 164 | 2016 |
| COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response A Zabalza, S Cárdenas‐Robledo, P Tagliani, G Arrambide, ... European journal of neurology 28 (10), 3384-3395, 2021 | 139 | 2021 |
| Multiple sclerosis registries in Europe–results of a systematic survey P Flachenecker, K Buckow, M Pugliatti, VB Kes, MA Battaglia, A Boyko, ... Multiple Sclerosis Journal 20 (11), 1523-1532, 2014 | 90 | 2014 |
| Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates M Sepúlveda, M Aldea, D Escudero, S Llufriu, G Arrambide, ... Multiple Sclerosis Journal 24 (14), 1843-1851, 2018 | 87 | 2018 |
| Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity MÁ Zapata, SB García, A Sánchez-Moltalvá, A Falcó, S Otero-Romero, ... British Journal of Ophthalmology 106 (4), 559-563, 2022 | 86 | 2022 |
| Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients J Río, À Rovira, M Tintoré, S Otero-Romero, M Comabella, ... Multiple Sclerosis Journal 24 (3), 322-330, 2018 | 78 | 2018 |
| Multiple sclerosis registries in Europe–An updated mapping survey A Glaser, A Stahmann, T Meissner, P Flachenecker, D Horáková, ... Multiple sclerosis and related disorders 27, 171-178, 2019 | 74 | 2019 |
| Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain S Otero-Romero, P Roura, J Solà, J Altimiras, J Sastre-Garriga, C Nos, ... Multiple Sclerosis Journal 19 (2), 245-248, 2013 | 69 | 2013 |
| The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS M Tintore, G Arrambide, S Otero-Romero, P Carbonell-Mirabent, J Río, ... Multiple Sclerosis Journal 26 (13), 1658-1669, 2020 | 64 | 2020 |
| Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis MI Zuluaga, S Otero-Romero, A Rovira, S Perez-Hoyos, G Arrambide, ... Neurology 92 (13), e1507-e1516, 2019 | 60 | 2019 |
| Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis C Tur, P Carbonell-Mirabent, Á Cobo-Calvo, S Otero-Romero, ... JAMA neurology 80 (2), 151-160, 2023 | 56 | 2023 |
| Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis M Tintore, S Otero-Romero, J Río, G Arrambide, B Pujal, C Tur, I Galán, ... Neurology 87 (13), 1368-1374, 2016 | 56 | 2016 |
| Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome M Tintore, A Cobo-Calvo, P Carbonell, G Arrambide, S Otero-Romero, ... Neurology 97 (17), e1641-e1652, 2021 | 45 | 2021 |
| Congenital transmission of Trypanosoma cruzi in non-endemic areas: evaluation of a screening program in a tertiary care hospital in Barcelona, Spain S Otero, E Sulleiro, I Molina, M Espiau, A Suy, A Martín-Nalda, C Figueras The American journal of tropical medicine and hygiene 87 (5), 832, 2012 | 41 | 2012 |
| Italian consensus on treatment of spasticity in multiple sclerosis G Comi, A Solari, L Leocani, D Centonze, S Otero‐Romero, ... European journal of neurology 27 (3), 445-453, 2020 | 40 | 2020 |
| Optic nerve topography in multiple sclerosis diagnosis: the utility of visual evoked potentials A Vidal-Jordana, A Rovira, G Arrambide, S Otero-Romero, J Río, ... Neurology 96 (4), e482-e490, 2021 | 36 | 2021 |
| TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis M Comabella, AB Caminero, S Malhotra, L Agulló, O Fernández, ... Neurology 80 (22), 2010-2016, 2013 | 32 | 2013 |
